Expert Opinion On Biological Therapy

Journal Title：Expert Opinion On Biological Therapy

Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy.

Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.

The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease.

The journal welcomes:

Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine

Drug evaluations reviewing the clinical data on a particular biological agent

Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice

Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:

Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;

Article Highlights – an executive summary of the author’s most critical points.

《生物治疗专家意见》（1471-2598；1744-7682）是一本 MEDLINE 索引的国际期刊，发表涉及生物治疗各个方面的同行评审研究。

每篇文章的结构都结合了作者自己对该主题对研究和临床实践的影响以及未来发展范围的专家意见。

读者包括医疗保健和生物制药行业的科学家和管理人员，以及其他与开发和应用生物疗法治疗人类疾病密切相关的人。

该期刊欢迎：

涵盖治疗性抗体和疫苗、肽和蛋白质、基因疗法和基因转移技术、细胞疗法和再生医学的评论

审查特定生物制剂临床数据的药物评估

原创研究论文，报告与生物制剂和生物治疗研究密切相关的临床研究结果临床实践

每篇评论的全面报道都由独特的专家精选格式补充，并包括以下部分：

专家意见——对文章中呈现的数据的个人看法，对未来可能重要的发展进行讨论，以及随着进一步研究产生更详细的结果，可能变得令人兴奋的研究途径；

文章重点——作者最关键观点的执行摘要。

Expert Opinion On Biological Therapy创刊于2001年，由Taylor and Francis Ltd.出版商出版，收稿方向涵盖生物工程与应用微生物 - 医学全领域，此刊是中等级别的SCI期刊，所以过审相对来讲不是特别难，但是该刊专业认可度不错，仍然是一本值得选择的SCI期刊 。平均审稿速度 一般,3-8周 ，影响因子指数3.6，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。